Anti-O1 antibodies and uses thereof

US12018068B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• Humabs BioMed SA · CH

Inventors

• Qun Wang · Gaithersburg, US
• Charles K. Stover · Gaithersburg, US
• Meghan Pennini · Gaithersburg, US
• Chew-Shun Chang · Gaithersburg, US
• Xiaodong Xiao · Gaithersburg, US
• Jamese Hilliard · Gaithersburg, US
• Gilad KAPLAN · Gaithersburg, US
• Davide Corti · Bellinzona, CH
• Elisabetta CAMERONI · Bellinzona, CH
• Martina Beltramello · Bellinzona, CH

Key dates

• Filing date: Aug 9, 2021
• Grant date: Jun 25, 2024
• Expiry date: Dec 6, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.